← All causality assessments
Expected pharmacological effect
Causality assessment · Expected pharmacological effect
Liraglutide and Impaired gastric emptying: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Liraglutide ↔ Impaired gastric emptying
n=592 co-reports · PRR 20.7 · ROR 21.0
Liraglutide is a GLP-1 receptor agonist; delayed gastric emptying underlies its nausea and vomiting and can produce gastroparesis-like symptoms (592 co-reports, PRR 20.7). As with semaglutide, the effect is intrinsic to class pharmacology and has prompted guidance to hold the drug before procedures requiring an empty stomach.
Regulatory basis: liraglutide (Victoza/Saxenda) prescribing information — nausea/vomiting and delayed gastric emptying.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Slowed emptying with therapy |
| Strength | met | PRR 20.7, large |
| Consistency | met | Consistent across GLP-1 agonists |
| Specificity | partial | Shared across the class |
| Biological gradient | met | Dose-related |
| Plausibility | met | GLP-1-mediated delay in gastric emptying |
| Coherence | met | Fits the mechanism |
| Experiment | met | Trials measured gastric emptying |
| Analogy | met | Analogous to semaglutide effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for liraglutide captured impaired gastric emptying as a tracked adverse event in a usable structure. Diabetes and weight-management trials measured gastric emptying as a pharmacodynamic measure rather than reporting gastroparesis as a coded event.